With Opdivo Approval, Bristol-Myers Arms for PD-1 Battle Against Merck's Keytruda
Friday, January 2, 2015
Source: Fierce Medical Devices
The Bristol-Myers Squibb-vs.-Merck match in melanoma is on. Bristol-Myers ($BMY) scored FDA approval for its cancer immunotherapy Opdivo (nivolumab) three months ahead of schedule, setting it up for a head-to-head contest against Merck's ($MRK) recent debut in the same class, Keytruda.